Video de la presentación «Novedades GOLD 2026», en el que se trataron, entre otros aspectos: cambios en diagnóstico de la EPOC, tratamiento, comparativa con GESEPOC, etc.
Discover how personalized COPD care integrates phenotypes, endotypes, GETomics, trajectome, syndemics, and treatable traits to improve patient outcomes.
Descubre las novedades del informe GOLD 2026 en este webinar gratuito desde la Universidad de Barcelona. Participa online o presencialmente.
Discover how the Treatable Traits approach transforms the management of asthma, bronchiectasis, and COPD through personalized precision medicine strategies.
Charla de Alvar Agistí en el H. La Paz sobre los orígenes de las enfermedades crónicas. tempranos en la sesión titulada: Orígenes tempranos de las enfermedades crónicas del adulto. El 24/09/2025
Study identifies 10-metabolite panel distinguishing COPD from healthy subjects with ~90% accuracy, highlighting lipid metabolism dysregulation and offering new diagnostic insights.
Discover the latest advances now pipeline new COPD treatments pipeline, from monoclonal antibodies to emerging therapies, and future opportunities in clinical development.
Expert consensus on patient-centred strategies to manage multimorbidity in COPD, aiming to improve outcomes and reduce disease burden.
The CAAT is a standardized 8-item questionnaire to assess health status in people with asthma, COPD, and other airway diseases. Now validated beyond COPD.
Commentary in the European Respiratory Journal (June 2025) reaffirming spirometry as the essential diagnostic tool for COPD.
